Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
2023 CMTA Annual Report
…committed to our mission of supporting the development of new treatments for CMT, improving the quality of life for those with CMT, and ultimately finding a cure. Your support, passion,…
CMTA 2023 Annual Report Download
…effective treatments to patients. The new projects approved in 2023 cover both axonal and demyelinating types of CMT, including treatment approaches applicable to multiple types, showcasing CMTA’s commitment to comprehensive…
CMTA 2023 Annual Report
…to address many types of CMT and bring effective treatments to patients. The new projects approved in 2023 cover both axonal and demyelinating types of CMT, including treatment approaches applicable…
2023 CMTA Annual Report
…in developing and commercializing treatments for rare diseases, Sue’s leadership marks a pivotal moment in our journey towards finding a cure for CMT. Sue brings a wealth of expertise to…
Fall 2024 CMTA Report
…treatments that will bring hope to the entire CMT community. Attendees left confident, knowing that every project supported by the CMTA brings us closer to effective treatments for all CMT,…
The CMTA Report Summer 2024_FOR GUIDES AND BROCHURES DOWNLOAD
cmtausa.org SUMMER 2024 CMTATHE REPORT RALLYING FOR SORD HEALTH, FITNESS, AND CMT EXPLORING CMT2A5 6 22> > > CAN AI CURE CMT? HOW ARTIFICIAL INTELLIGENCE IS REVOLUTIONIZING THE DIAGNOSIS, TREATMENT,…
STAR_Webinar_Transcript
…with CMT. Nevertheless, for people like you and for me, 10 years feels like an eternity when there are still no viable treatments for CMT. On the other hand, 10…
Managing_Neuropathic_Pain_Dr_Steven_Scherer
…calcium channel a2-d ligands (i.e., gabapentin and pregabalin), and topical lidocaine” were considered first-line treatments, with opioids as “generally second-line treatments”. “Third-line treatments that could also be used as second-line…
2022 Annual Report_spreads
…leading academic labs, clinical centers and pharmaceutical and biotech companies to advance scientific knowledge, increase clinical trial readiness and accelerate progress towards treatments for CMT. Today, CMTA-STAR is the largest…
NeuroMeds
…placement of some agents. As with any treatment, the risk of neuropathy exacerbation must be weighed against expected treatment benefits and available equivalent, alternative treatments. Despite the limitations of this…